{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037592","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2026-08-13T12:15:11+00:00","discovered_at":"2026-08-13T12:20:03.845897+00:00","generated_at":"2026-08-13T12:20:19.949435+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pulmatrix Q2 net loss $1.0M; cash $2.2M; merger with Eos on track for Q3 close","bullets":["Q2 net loss $1.036M ($0.29/share) vs $1.549M loss year ago; R&D expenses <$0.1M.","Cash and equivalents $2.2M plus $0.7M restricted; going concern assumption within one year.","Merger with Eos SENOLYTIX expected to close Q3 2026; Form S-4 filed July 9, amended Aug 3.","G&A expenses down to $1.0M from $1.5M; all clinical development on hold to license/monetize assets.","iSPERSE patent portfolio ~142 granted patents, 17 US; PUR1900 Phase 3 in India by Cipla."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037592","json":"https://secwatch.observer/filing/0001493152-26-037592.json","markdown":"https://secwatch.observer/filing/0001493152-26-037592.md","text":"https://secwatch.observer/filing/0001493152-26-037592.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315226037592/0001493152-26-037592-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315226037592/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T12:20:19.949435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}